Novo and existing backer GV participated in a round that lifted the heart disease drug developer's overall funding to more than $215m.
US-based cardiovascular disease drug developer Verve Therapeutics closed a $94m series B round yesterday featuring pharmaceutical firm Novo and GV, a corporate venturing subsidiary of internet and technology group Alphabet. Wellington Management and Casdin Capital co-led the round, which included Redmile Group, Janus Henderson Investors, Cormorant Asset Management, Rock Springs Capital, Logos Capital, Surveyor Capital,…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
